Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study

Abstract Precision medicine is associated with favorable outcomes in selected patients with cancer. Herein, we report an interim analysis of IMPACT2, an ongoing randomized study evaluating genomic profiling and targeted agents in metastatic cancer. Patients with metastatic cancer underwent tumor gen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Apostolia Maria Tsimberidou, David S. Hong, Siqing Fu, Daniel D. Karp, Sarina Piha-Paul, Merrill S. Kies, Vinod Ravi, Vivek Subbiah, Sunil M. Patel, Shi-Ming Tu, Filip Janku, John Heymach, Amber Johnson, Carrie Cartwright, Li Zhao, Jianhua Zhang, Donald A. Berry, David J. Vining, Andrew Futreal, Vincent A. Miller, Funda Meric-Bernstam
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/33315794ca1f4daf8eba5da8574c8e3f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:33315794ca1f4daf8eba5da8574c8e3f
record_format	dspace
spelling	oai:doaj.org-article:33315794ca1f4daf8eba5da8574c8e3f2021-12-02T16:30:41ZPrecision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study10.1038/s41698-021-00159-22397-768Xhttps://doaj.org/article/33315794ca1f4daf8eba5da8574c8e3f2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00159-2https://doaj.org/toc/2397-768XAbstract Precision medicine is associated with favorable outcomes in selected patients with cancer. Herein, we report an interim analysis of IMPACT2, an ongoing randomized study evaluating genomic profiling and targeted agents in metastatic cancer. Patients with metastatic cancer underwent tumor genomic profiling (ClinialTrials.gov: NCT02152254), and 69 patients met the criteria for randomization. Tumor board and multidisciplinary review of molecular alterations optimized treatment selection. From 5/2014 to 4/2017, 320 patients (median age, 63 years; men, 47%) had tumor molecular aberrations, and 213 (66.56%) received anticancer therapy. The most frequently mutated genes were TP53 (42%), KRAS (16%), PIK3CA (12%), and CDKN2A (11%). The median OS was 10.9 months (95% CI, 8.8–12.9). OS was shorter in patients with higher tumor mutational burden. Independent factors associated with shorter OS were age ≥60 years, liver metastases, low albumin levels, high LDH levels, and KRAS and TP53 mutations. Outcomes for randomized patients will be reported after completion of the study.Apostolia Maria TsimberidouDavid S. HongSiqing FuDaniel D. KarpSarina Piha-PaulMerrill S. KiesVinod RaviVivek SubbiahSunil M. PatelShi-Ming TuFilip JankuJohn HeymachAmber JohnsonCarrie CartwrightLi ZhaoJianhua ZhangDonald A. BerryDavid J. ViningAndrew FutrealVincent A. MillerFunda Meric-BernstamNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Apostolia Maria Tsimberidou David S. Hong Siqing Fu Daniel D. Karp Sarina Piha-Paul Merrill S. Kies Vinod Ravi Vivek Subbiah Sunil M. Patel Shi-Ming Tu Filip Janku John Heymach Amber Johnson Carrie Cartwright Li Zhao Jianhua Zhang Donald A. Berry David J. Vining Andrew Futreal Vincent A. Miller Funda Meric-Bernstam Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
description	Abstract Precision medicine is associated with favorable outcomes in selected patients with cancer. Herein, we report an interim analysis of IMPACT2, an ongoing randomized study evaluating genomic profiling and targeted agents in metastatic cancer. Patients with metastatic cancer underwent tumor genomic profiling (ClinialTrials.gov: NCT02152254), and 69 patients met the criteria for randomization. Tumor board and multidisciplinary review of molecular alterations optimized treatment selection. From 5/2014 to 4/2017, 320 patients (median age, 63 years; men, 47%) had tumor molecular aberrations, and 213 (66.56%) received anticancer therapy. The most frequently mutated genes were TP53 (42%), KRAS (16%), PIK3CA (12%), and CDKN2A (11%). The median OS was 10.9 months (95% CI, 8.8–12.9). OS was shorter in patients with higher tumor mutational burden. Independent factors associated with shorter OS were age ≥60 years, liver metastases, low albumin levels, high LDH levels, and KRAS and TP53 mutations. Outcomes for randomized patients will be reported after completion of the study.
format	article
author	Apostolia Maria Tsimberidou David S. Hong Siqing Fu Daniel D. Karp Sarina Piha-Paul Merrill S. Kies Vinod Ravi Vivek Subbiah Sunil M. Patel Shi-Ming Tu Filip Janku John Heymach Amber Johnson Carrie Cartwright Li Zhao Jianhua Zhang Donald A. Berry David J. Vining Andrew Futreal Vincent A. Miller Funda Meric-Bernstam
author_facet	Apostolia Maria Tsimberidou David S. Hong Siqing Fu Daniel D. Karp Sarina Piha-Paul Merrill S. Kies Vinod Ravi Vivek Subbiah Sunil M. Patel Shi-Ming Tu Filip Janku John Heymach Amber Johnson Carrie Cartwright Li Zhao Jianhua Zhang Donald A. Berry David J. Vining Andrew Futreal Vincent A. Miller Funda Meric-Bernstam
author_sort	Apostolia Maria Tsimberidou
title	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
title_short	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
title_full	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
title_fullStr	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
title_full_unstemmed	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
title_sort	precision medicine: preliminary results from the initiative for molecular profiling and advanced cancer therapy 2 (impact2) study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/33315794ca1f4daf8eba5da8574c8e3f
work_keys_str_mv	AT apostoliamariatsimberidou precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT davidshong precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT siqingfu precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT danieldkarp precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT sarinapihapaul precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT merrillskies precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT vinodravi precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT viveksubbiah precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT sunilmpatel precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT shimingtu precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT filipjanku precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT johnheymach precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT amberjohnson precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT carriecartwright precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT lizhao precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT jianhuazhang precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT donaldaberry precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT davidjvining precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT andrewfutreal precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT vincentamiller precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study AT fundamericbernstam precisionmedicinepreliminaryresultsfromtheinitiativeformolecularprofilingandadvancedcancertherapy2impact2study
_version_	1718383920803741696

Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study

Ejemplares similares